[Agnostics of immunological therapies in monotherapy and in association: impacts on clinical governance and on the patient's journey.]

From "one-size-fits-all medicine" to stratified and precision medicine, to network oncology: the paradigm shift in therapeutic approaches in oncology is requiring new care and governance models. Molecular tumor board, network analysis, real-world evidence: only through new tools that do not reduce the complexity of the challenges will it be possible to introduce innovation into the healthcare system.